查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2095104

生物製藥第三方物流市場：全球預測，2026-2032年

Biopharmaceutical Third Party Logistics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生物製藥第三方物流市場規模將達到 3,842.3 億美元，複合年成長率為 15.51%。

主要市場統計數據
基準年 2025 1400.3億美元
預計年份：2026年 1610.4億美元
預測年份 2032 3842.3億美元
複合年成長率 (%) 15.51%

生物製藥第三方物流正日益成為製藥企業、生物技術開發公司、臨床研究機構、專業批發商、醫院和藥房等機構的重要營運基礎，這些機構需要對高價值治療藥物進行受監管、溫控且可追溯的運輸。該行業為生技藥品、疫苗、細胞和基因療法、血漿衍生產品、生物相似藥以及其他對溫度敏感的藥物提供儲存、運輸、包裝、貼標、訂單處理、清關、逆向物流和最後一公里配送服務。推動此需求的因素包括生物製藥產品組合日益複雜、GDP（藥品良好分銷規範）要求更加嚴格、臨床試驗全球化，以及需要在受控室溫、冷藏、冷凍和超低溫環境下維持檢驗的低溫運輸完整性。隨著生物製藥供應鏈日益以患者為中心，監管也日趨嚴格，物流合作夥伴不僅需要提供實體配送能力，還需要提供品管系統、數位貨運可視性、路線合格、偏差控制和完整的儲存歷史管理。該產業具有的 SEO 相關主題包括生物製藥第三方物流、藥品低溫運輸物流、生技藥品物流、臨床試驗物流、溫控倉儲、特用藥品分銷和符合 GDP 標準的藥品物流。

生物製藥物流產業的變革

生物製藥第三方物流(3PL) 的格局正在從以資產為基礎的配送模式轉變為以品質主導、數據驅動的整合式供應鏈協調模式。生物製藥和先進療法的擴張，使得經過驗證的包裝、即時溫度監控、基於風險的路線規劃以及穩定性範圍窄的產品的特殊處理等要素在營運中的重要性日益凸顯。臨床試驗的去中心化也正在改變物流需求，更加重視直接送藥給病患、居家醫療支援、對照藥物採購、臨床實驗點的快速補給。同時，全球監管要求迫使物流供應商加強文件記錄、溫度偏差調查、供應商合格和審計準備。永續性也是推動這一轉變的重要因素，可重複使用的低溫運輸包裝、最佳化的運輸路線、減少對乾冰的依賴以及節能倉儲等措施正在整個藥品分銷網路中得到廣泛應用。鑑於最近供應鏈中斷的情況，供應鏈韌性變得同樣重要，相關人員正在轉向多樣化儲存地點、改進緊急時應對計畫以及實施數位控制塔，以實現端到端的可視性。

人工智慧對製藥業第三方物流的累積影響

人工智慧 (AI) 透過增強預測能力、自動化和決策支持，在生物製藥第三方物流(3PL) 領域帶來持續累積，同時又不取代經過檢驗的品質系統或人工監督。 AI 驅動的分析可以輔助低溫運輸中的需求預測、庫存佈局、運輸風險評估、溫度偏差預測、路線最佳化和運力規劃。在溫控運輸中，機器學習模型可用於分析歷史運輸路線績效、天氣模式、清關時間、包裝特徵和承運商可靠性，從而在出貨前識別高風險貨物。在倉儲營運中，AI 可以最佳化倉位分配、人員配置規劃、批次追蹤和偏差趨勢分析，而電腦視覺和自動化可以提高檢驗一致性和操作準確性。在臨床試驗物流中，AI 可以輔助以病人為中心的交付時間表、試驗點補貨和臨床實驗藥物管理。當 AI 整合到經過檢驗的工作流程中，並由準確的主資料、網路安全措施、審計追蹤、人工審核和符合藥品品質標準的監管管治提供支援時，其影響將最為顯著。

亞太、北美、歐洲和新興地區的關鍵區域洞察

由於生物製藥生產的擴張、臨床試驗活動的活性化、疫苗分發需求的成長以及主要經濟體醫療保健服務的改善，亞太地區已成為生物製藥物流的重點關注區域。該地區的物流複雜性受到溫度波動、跨境海關程序差異、島嶼地理環境以及連接製造地與醫院和專科藥房的合格低溫運輸基礎設施需求等因素的影響。北美市場環境成熟且監管嚴格，生物製藥、專科藥物、細胞和基因療法以及涉及直接患者配送的臨床試驗的物流需求持續成長，推動了對先進低溫運輸能力、檢驗的倉儲、可序列化的分銷以及即時運輸可視性的需求。在拉丁美洲，隨著醫療保健系統擴大專科藥物的覆蓋範圍，物流的重要性日益凸顯，但分銷通常需要謹慎管理海關延誤、基礎設施差異、安全風險以及長途國內運輸路線的溫度偏差風險。在歐洲，完善的藥品良好分銷規範 (GDP) 框架、高密度多模態網路以及對跨境藥品分銷的強勁需求都是其優勢所在，合規性、序列化和永續性是其物流戰略的關鍵要素。中東地區正透過對機場貨運設施、冷庫和藥品進口基礎設施的投資，不斷強化其作為區域醫療和物流門戶的地位。同時，在非洲，儘管醫療需求不斷成長，但也面臨著許多營運挑戰，包括分散的分銷網路、部分地區低溫運輸覆蓋範圍有限、電力供應可靠性受限，以及疫苗、生技藥品和基本藥物「最後一公里」物流的韌性不足等問題。

該小組對東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約提出了重要見解。

在東協，隨著成員國加強藥品貿易、醫療基礎設施和區域分銷走廊建設，對能夠適應不同監管和海關環境的溫控運輸的需求日益成長，這提升了東協在生物製藥第三方物流的重要性。全球鏈聯盟（GCC）憑藉其戰略性的航空貨運網路、對醫療保健領域的投資以及對可靠低溫運輸系統的需求（該系統能夠支持在高溫氣候下進口的生技藥品、疫苗和特藥），正在崛起成為重要的生物製藥物流樞紐。歐盟為藥品物流提供了最完善的商業環境之一，擁有統一的監管原則、藥品良好分銷規範（GDP）要求、藥品安全法規下的序列化要求以及支持持續品質監控的跨境分銷網路。金磚國家在生物製藥物流發展中扮演著核心角色，因為它們擁有大規模的患者群體、不斷擴大的國內藥品生產、日益成長的臨床研究參與度以及對專科藥物日益成長的需求，同時，它們在海關、基礎設施和區域合規方面也需要採取個性化的方法。七國集團（G7）國家憑藉先進的生物製藥創新、嚴格的監管標準、完善的專業藥品分銷網路以及積極採用數位化品質體系，持續發揮著重要的影響力。雖然北約成員國並非醫療衛生貿易集團，但它們在戰略基礎設施、運輸走廊和韌性方面共用的優先事項，這些事項會影響藥品儲備系統、緊急醫療物流、安全的供應鏈規劃以及成員國之間基本藥物分銷的連續性。

主要國家生物製藥第三方物流的發展趨勢

美國在生物製藥物流的複雜性方面處於領先地位，這主要源於其廣泛的生技藥品研發、透過專業藥房進行的分銷、臨床試驗網路以及對國內外運輸路線低溫運輸可視性的高需求。加拿大高度重視監管合規性，並致力於在其廣闊的地域範圍內提供可靠的溫控配送服務，這需要周密的規劃來應對極端季節性氣候變遷和偏遠地區的挑戰。墨西哥與北美藥品供應鏈的聯繫日益緊密，跨境貿易、製造地商間的合作以及醫療保健需求都為合規的物流服務提供了支持。巴西是拉丁美洲重要的醫療保健市場，其生物製藥分銷依賴於對長途運輸、區域基礎設施差異、進口程序以及向公共和私人醫療機構進行溫控配送的有效管理。英國仍然是臨床研究和生命科學物流的領先中心，其重點在於遵守GDP法規、擁有健全的海關系統以及處理先進療法。德國擁有強大的製藥生產基地、與中歐的緊密聯繫以及成熟的低溫運輸倉儲能力。法國擁有完善的醫療基礎設施、生物製藥生產和臨床試驗活動，這些都支撐著對合格物流合作夥伴的需求。俄羅斯由於其地理面積廣、氣候多變以及複雜的貿易環境，對藥品運輸提出了獨特的物流要求。義大利和西班牙是歐洲重要的醫藥和臨床研究市場，醫院配送、專科藥品和溫控運輸持續推動物流專業化的發展。中國透過不斷擴大的生物製藥生產、國內創新和大規模的醫療保健需求，在全球生物製藥供應鏈的演進中扮演核心角色。同時，印度在藥品生產、臨床研究支援和成本效益型物流發展方面佔據關鍵地位，其低溫運輸需求也不斷成長。日本擁有嚴格的標準和先進的醫療基礎設施，對先進療法、生物製藥和精準醫療產品的可靠且以品質為中心的物流需求旺盛。澳洲的物流環境具有地域遼闊、人口集中在沿海城市、生物安全措施以及透過溫控配送向偏遠地區提供服務等特性。韓國正在加強其在生物製藥製造和臨床研究領域的地位，這導致對檢驗的低溫運輸儲存、國際分銷和高品質藥品物流的需求日益成長。

生物製藥物流負責人實用建議

產業領導者應優先考慮以品質主導的物流策略，使低溫運輸營運符合藥品監管要求、產品穩定性要求和病人安全目標。各組織必須通過對GDP（藥品良好分銷規範）合規性、溫度分佈圖、偏差響應、網路安全、業務永續營運計劃、資料完整性和審計準備情況的書面評估，對物流合作夥伴進行認證。對於高價值生物製藥和臨床試驗材料，合格數位化視覺化至關重要，包括即時監控、電子交貨證書、控制塔分析、檢驗的數據收集和預測性風險警報。領導者還應為每條運輸路線制定風險概況，維護經認證的包裝配置，並建立針對溫度偏差、海關延誤、承運商中斷和召回的升級程序。對於先進療法和分散式臨床試驗，物流模式必須支援精確的交付時間、身分鏈管理、必要的低溫處理以及製造商、研究機構、患者和醫療保健提供者之間的協調溝通。永續性必須透過可重複使用的包裝材料、整合和最佳化的運輸、節能設施和負責任的乾冰管理來實現。最後，各組織應透過多樣化儲存地點、檢驗緊急時應對計畫以及維持有關服務水準、品質事件和交付可靠性的透明績效指標來增強韌性。

調查方法

本執行摘要採用結構化的二手研究方法編寫，重點關注來自官方監管指南、藥品分銷標準、醫療物流文件、臨床試驗管理文獻、海關和貿易文件以及公開政策資訊來源的檢驗且有數據支持的行業證據。研究途徑從服務能力、溫度要求、法規遵循、區域物流、臨床試驗藥物分銷和數位化供應鏈轉型等角度評估生物製藥產業的第三方物流 (3PL)。透過定性檢驗法整合研究成果，將監管預期與低溫運輸物流、特藥分銷、倉儲和運輸方面的實際產業實踐進行比較。透過已記錄的醫療基礎設施狀況、藥品貿易的重要性、監管成熟度、物流連通性、低溫運輸準備情況以及進出口營運條件，評估區域、群體和國家層面的具體情況。本調查方法刻意排除無根據的預測、推測性的規模估算、市場佔有率假設和檢驗的商業性聲明。相反，它側重於對營運促進因素、合規要求、技術應用和供應鏈風險因素的實證解讀。

結論

生物製藥第三方物流(3PL) 正在發展成為安全、合規且具韌性的醫療服務交付的策略驅動力。生物製藥、疫苗、專科藥物和先進療法的日益普及，推動了對符合 GDP 標準的倉儲、經驗證的溫控運輸、數位可視性和專業處理技術的需求。人工智慧、即時監控、永續低溫運輸包裝和基於風險的路線規劃正在重塑物流網路應對複雜性的方式，而基礎設施、法規、海關程序和醫療服務可近性方面的區域差異，則持續影響執行策略。能夠將品質管治、數位智慧、韌性網路設計和以患者為中心的交付模式相結合的組織，將更有能力支持生物製藥供應鏈轉型的下一階段。首要任務依然明確：在滿足監管要求並保障患者療效的同時，確保產品從源頭到患者的完整性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：生物製藥第三方物流市場：依產品類型分類

  • 細胞療法
    • 樹突細胞療法
    • 幹細胞療法
  • 基因治療
  • 單株抗體
  • 重組蛋白
  • 疫苗
    • 失活
    • 減毒活病毒疫苗

第8章：生物製藥第三方物流市場：依服務類型分類

  • 分銷管理
  • 包裝和標籤
  • 運輸
    • 空運
      • 航空快遞
      • 標準空氣
    • 鐵路運輸
    • 道路運輸
    • 海上運輸
  • 倉儲

第9章：生物製藥第三方物流市場：依溫度範圍分類

  • 環境的
  • 冷藏
    • 監控冷藏
    • 標準冷凍
  • 室溫控制
    • 監控房間溫度控制
    • 標準室溫控制
  • 冰凍
    • 標準冷凍
    • 超冷凍

第10章：生物製藥第三方物流市場：依運輸方式分類

  • 空運
  • 鐵路貨運
  • 道路運輸
  • 海上運輸

第11章：生物製藥第三會物流市場：依包裝類型分類

  • 活性包裝
  • 被動式封裝

第12章：生物製藥第三方物流市場：依最終用戶分類

  • 生物製藥製造商
  • 契約製造組織
  • 受託研究機構
  • 診斷檢查室
  • 醫院和診所
    • 當地醫院
    • 研究醫院

第13章：生物製藥第三方物流市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：生物製藥第三會物流市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：生物製藥第三方物流市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AmerisourceBergen Corporation
  • CH Robinson Worldwide, Inc.
  • Cardinal Health, Inc.
  • Cencora, Inc.
  • CEVA Logistics AG
  • Dachser SE
  • DB Schenker Logistics Germany AG & Co. KG
  • DHL International GmbH
  • DSV A/S
  • EVERSANA Life Science Services LLC
  • Expeditors International of Washington, Inc.
  • FedEx Corporation
  • GEODIS SA
  • Hitachi Transport System, Ltd.（LOGISTEED, Ltd.）
  • Kuehne+Nagel International AG
  • McKesson Corporation
  • Nippon Express Holdings, Inc.
  • SF Holding Co., Ltd.
  • Sinotrans Limited
  • Thermo Fisher Scientific Inc.
  • Toll Holdings Pty Ltd
  • United Parcel Service of America, Inc.
  • XPO, Inc.
  • Yusen Logistics Co., Ltd.
Product Code: MRR-563BF1FCF7FA

The Biopharmaceutical Third Party Logistics Market is projected to grow by USD 384.23 billion at a CAGR of 15.51% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 140.03 billion
Estimated Year [2026] USD 161.04 billion
Forecast Year [2032] USD 384.23 billion
CAGR (%) 15.51%

Biopharmaceutical third party logistics is becoming a critical operating layer for pharmaceutical manufacturers, biotechnology developers, clinical research organizations, specialty distributors, hospitals, and pharmacies that require compliant, temperature-controlled, and traceable movement of high-value therapies. The sector supports storage, transportation, packaging, labeling, order fulfillment, customs handling, reverse logistics, and last-mile delivery of biologics, vaccines, cell and gene therapies, plasma-derived products, biosimilars, and other temperature-sensitive medicines. Demand is being shaped by the rising complexity of biologic drug portfolios, stricter Good Distribution Practice requirements, growing clinical trial globalization, and the need to maintain validated cold chain integrity across controlled room temperature, refrigerated, frozen, and ultra-low-temperature environments. As biopharmaceutical supply chains become more patient-centric and more regulated, logistics partners are expected to provide not only physical distribution capacity but also quality management systems, digital shipment visibility, lane qualification, deviation management, and documented chain-of-custody controls. SEO-relevant themes defining this industry include biopharmaceutical third party logistics, pharmaceutical cold chain logistics, biologics logistics, clinical trial logistics, temperature-controlled warehousing, specialty pharmaceutical distribution, and GDP-compliant pharma logistics.

Transformative Shifts in the Biopharmaceutical Logistics Landscape

The biopharmaceutical third party logistics landscape is shifting from asset-based distribution toward integrated, quality-led, data-enabled supply chain orchestration. The expansion of biologics and advanced therapies has increased the operational importance of validated packaging, real-time temperature monitoring, risk-based route planning, and specialized handling for products with narrow stability profiles. Clinical trial decentralization is also transforming logistics requirements, with greater emphasis on direct-to-patient delivery, home healthcare support, comparator drug sourcing, and rapid resupply to investigator sites. At the same time, global regulatory expectations are pushing logistics providers to strengthen documentation, temperature excursion investigation, supplier qualification, and audit readiness. Sustainability is another transformative force, as reusable cold chain packaging, optimized transport lanes, reduced dry ice dependence, and energy-efficient warehousing gain attention across pharmaceutical distribution networks. Supply chain resilience has become equally important following recent disruptions, prompting stakeholders to diversify storage locations, improve contingency planning, and deploy digital control towers for end-to-end visibility.

Cumulative Impact of Artificial Intelligence on Pharma 3PL

Artificial intelligence is creating cumulative improvements across biopharmaceutical third party logistics by enhancing prediction, automation, and decision support without replacing the need for validated quality systems and human oversight. AI-enabled analytics can support demand sensing, inventory positioning, shipment risk scoring, temperature excursion prediction, route optimization, and capacity planning for cold chain logistics. In temperature-controlled transportation, machine learning models can analyze historical lane performance, weather patterns, customs dwell times, packaging profiles, and carrier reliability to identify higher-risk shipments before dispatch. In warehousing, AI can strengthen slotting, labor planning, batch traceability, and deviation trend analysis, while computer vision and automation can improve inspection consistency and operational accuracy. For clinical trial logistics, AI can help coordinate patient-centric delivery windows, site replenishment, and investigational product accountability. The largest impact is achieved when AI is embedded into validated workflows, supported by clean master data, cybersecurity controls, audit trails, human review, and regulatory governance aligned with pharmaceutical quality standards.

Key Regional Insights Across Asia-Pacific, North America, Europe, and Emerging Regions

Asia-Pacific is a high-priority region for biopharmaceutical third party logistics due to expanding biologics manufacturing, rising clinical trial activity, increasing vaccine distribution requirements, and growing healthcare access across major economies. The region's logistics complexity is shaped by temperature variability, cross-border customs differences, island geographies, and the need for qualified cold chain infrastructure connecting manufacturing hubs with hospitals and specialty pharmacies. North America remains a mature and highly regulated market environment where biologics, specialty drugs, cell and gene therapies, and direct-to-patient clinical trial logistics continue to drive demand for advanced cold chain capabilities, validated warehousing, serialization-aligned distribution, and real-time shipment visibility. Latin America is gaining importance as healthcare systems expand access to specialty medicines, though distribution often requires careful management of customs delays, infrastructure variability, security risks, and temperature excursion exposure across long domestic routes. Europe benefits from well-established Good Distribution Practice frameworks, dense multimodal transport networks, and strong demand for cross-border pharmaceutical distribution, with compliance, serialization, and sustainability shaping logistics strategies. The Middle East is strengthening its role as a regional healthcare and logistics gateway, supported by investments in airport cargo facilities, cold storage, and pharmaceutical import infrastructure, while Africa presents both growing healthcare demand and significant operational challenges, including fragmented distribution networks, limited cold chain reach in certain areas, power reliability constraints, and the need for resilient last-mile logistics for vaccines, biologics, and essential medicines.

Key Group Insights for ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN is increasingly relevant for biopharmaceutical third party logistics as member economies strengthen pharmaceutical trade, healthcare infrastructure, and regional distribution corridors, creating demand for temperature-controlled transport that can navigate diverse regulatory and customs environments. The GCC is emerging as an important biopharmaceutical logistics hub due to strategic air cargo connectivity, healthcare investment, and the need for reliable cold chain systems supporting imported biologics, vaccines, and specialty medicines in high-temperature climates. The European Union provides one of the most structured operating environments for pharmaceutical logistics, with harmonized regulatory principles, Good Distribution Practice expectations, serialization requirements under medicines safety rules, and cross-border distribution networks that support consistent quality oversight. BRICS countries are central to biopharmaceutical logistics development because they combine large patient populations, expanding domestic pharmaceutical production, increasing clinical research participation, and growing demand for specialty medicines, while also requiring tailored approaches to customs, infrastructure, and regional compliance. G7 economies remain influential due to advanced biopharmaceutical innovation, strict regulatory standards, sophisticated specialty distribution networks, and strong adoption of digital quality systems. NATO countries, while not a healthcare trade bloc, share strategic infrastructure, transport corridors, and resilience priorities that can influence pharmaceutical preparedness, emergency medical logistics, secure supply chain planning, and continuity of essential medicine distribution across member states.

Key Country Insights in Biopharmaceutical Third Party Logistics

The United States leads in biopharmaceutical logistics complexity due to extensive biologics development, specialty pharmacy distribution, clinical trial networks, and high demand for cold chain visibility across domestic and international lanes. Canada places strong emphasis on regulatory compliance and reliable temperature-controlled distribution across vast geography, where seasonal extremes and remote communities require robust planning. Mexico is increasingly connected to North American pharmaceutical supply chains, with cross-border trade, manufacturing links, and healthcare demand supporting compliant logistics services. Brazil is a major Latin American healthcare market where biopharmaceutical distribution depends on effective management of long transport distances, regional infrastructure differences, import processes, and temperature-controlled delivery into public and private healthcare channels. The United Kingdom remains a key center for clinical research and life sciences logistics, with emphasis on GDP compliance, customs readiness, and advanced therapy handling. Germany benefits from strong pharmaceutical manufacturing, central European connectivity, and mature cold chain warehousing capabilities. France combines established healthcare infrastructure, biopharmaceutical production, and clinical trial activity that support demand for qualified logistics partners. Russia presents unique logistics requirements due to geographic scale, climate variability, and complex trade conditions affecting pharmaceutical movement. Italy and Spain are important European pharmaceutical and clinical research markets where hospital distribution, specialty medicines, and temperature-controlled transport continue to support logistics specialization. China is central to global biopharmaceutical supply chain evolution through expanding biologics manufacturing, domestic innovation, and large-scale healthcare demand, while India is highly significant for pharmaceutical production, clinical research support, and cost-efficient logistics development with rising cold chain requirements. Japan requires highly reliable, quality-focused logistics for advanced therapies, biologics, and precision healthcare products, supported by stringent standards and sophisticated healthcare infrastructure. Australia's logistics environment is shaped by long distances, population concentration in coastal cities, biosecurity controls, and the need to serve remote areas with temperature-assured distribution. South Korea is strengthening its position in biologics manufacturing and clinical research, increasing the need for validated cold chain storage, international distribution, and high-quality pharma logistics execution.

Actionable Recommendations for Biopharmaceutical Logistics Leaders

Industry leaders should prioritize quality-led logistics strategies that align cold chain execution with pharmaceutical regulatory expectations, product stability requirements, and patient safety outcomes. Organizations should qualify logistics partners using documented assessments of GDP compliance, temperature mapping, deviation handling, cybersecurity, business continuity planning, data integrity, and audit readiness. Investment in digital visibility is essential, including real-time monitoring, electronic proof of delivery, control tower analytics, validated data capture, and predictive risk alerts for high-value biologics and clinical trial materials. Leaders should also develop lane-specific risk profiles, maintain qualified packaging configurations, and establish escalation protocols for temperature excursions, customs delays, carrier disruptions, and recalls. For advanced therapies and decentralized trials, logistics models should support precise delivery windows, chain-of-identity management, cryogenic handling where needed, and coordinated communication across manufacturers, sites, patients, and healthcare providers. Sustainability should be embedded through reusable packaging, optimized shipment consolidation, energy-efficient facilities, and responsible dry ice management. Finally, organizations should build resilience by diversifying storage nodes, testing contingency plans, and maintaining transparent performance metrics across service levels, quality events, and delivery reliability.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified, data-backed industry evidence from public regulatory guidance, pharmaceutical distribution standards, healthcare logistics documentation, clinical trial operations literature, customs and trade references, and publicly available policy sources. The research framework evaluates biopharmaceutical third party logistics across service functions, temperature requirements, regulatory compliance, regional infrastructure, clinical trial distribution, and digital supply chain transformation. Insights are synthesized through qualitative triangulation, comparing regulatory expectations with observable industry practices in cold chain logistics, specialty pharmaceutical distribution, warehousing, and transportation. Regional, group, and country insights are assessed through documented healthcare infrastructure conditions, pharmaceutical trade relevance, regulatory maturity, logistics connectivity, cold chain readiness, and import-export operating conditions. The methodology intentionally excludes unsupported projections, speculative sizing, market share assumptions, and unverified commercial claims, focusing instead on evidence-based interpretation of operational drivers, compliance needs, technology adoption, and supply chain risk factors.

Conclusion

Biopharmaceutical third party logistics is evolving into a strategic enabler of safe, compliant, and resilient healthcare delivery. The growing use of biologics, vaccines, specialty medicines, and advanced therapies is increasing the need for GDP-compliant warehousing, validated temperature-controlled transportation, digital visibility, and specialized handling expertise. Artificial intelligence, real-time monitoring, sustainable cold chain packaging, and risk-based route planning are reshaping how logistics networks manage complexity, while regional differences in infrastructure, regulation, customs processes, and healthcare access continue to influence execution strategies. Organizations that combine quality governance, digital intelligence, resilient network design, and patient-centric delivery models will be better positioned to support the next phase of biopharmaceutical supply chain transformation. The central priority remains clear: maintaining product integrity from origin to patient while meeting regulatory expectations and protecting patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biopharmaceutical Third Party Logistics Market, by Product Type

  • 7.1. Introduction
  • 7.2. Cell Therapies
    • 7.2.1. Dendritic Cell Therapies
    • 7.2.2. Stem Cell Therapies
  • 7.3. Gene Therapies
  • 7.4. Monoclonal Antibodies
  • 7.5. Recombinant Proteins
  • 7.6. Vaccines
    • 7.6.1. Inactivated
    • 7.6.2. Live Attenuated

8. Biopharmaceutical Third Party Logistics Market, by Service Type

  • 8.1. Introduction
  • 8.2. Distribution Management
  • 8.3. Packaging & Labeling
  • 8.4. Transportation
    • 8.4.1. Air Transport
      • 8.4.1.1. Express Air
      • 8.4.1.2. Standard Air
    • 8.4.2. Rail Transport
    • 8.4.3. Road Transport
    • 8.4.4. Sea Transport
  • 8.5. Warehousing

9. Biopharmaceutical Third Party Logistics Market, by Temperature Range

  • 9.1. Introduction
  • 9.2. Ambient
  • 9.3. Chilled
    • 9.3.1. Monitored Chilled
    • 9.3.2. Standard Chilled
  • 9.4. Controlled Room Temperature
    • 9.4.1. Monitored Controlled Room Temperature
    • 9.4.2. Standard Controlled Room Temperature
  • 9.5. Frozen
    • 9.5.1. Standard Frozen
    • 9.5.2. Ultra Frozen

10. Biopharmaceutical Third Party Logistics Market, by Mode Of Transportation

  • 10.1. Introduction
  • 10.2. Air Freight
  • 10.3. Rail Freight
  • 10.4. Road Transport
  • 10.5. Sea Freight

11. Biopharmaceutical Third Party Logistics Market, by Packaging Type

  • 11.1. Introduction
  • 11.2. Active Packaging
  • 11.3. Passive Packaging

12. Biopharmaceutical Third Party Logistics Market, by End User

  • 12.1. Introduction
  • 12.2. Biopharmaceutical Manufacturers
  • 12.3. Contract Manufacturing Organizations
  • 12.4. Contract Research Organizations
  • 12.5. Diagnostic Laboratories
  • 12.6. Hospitals & Clinics
    • 12.6.1. Community Hospitals
    • 12.6.2. Research Hospitals

13. Biopharmaceutical Third Party Logistics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Biopharmaceutical Third Party Logistics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biopharmaceutical Third Party Logistics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AmerisourceBergen Corporation
  • 17.2. C.H. Robinson Worldwide, Inc.
  • 17.3. Cardinal Health, Inc.
  • 17.4. Cencora, Inc.
  • 17.5. CEVA Logistics AG
  • 17.6. Dachser SE
  • 17.7. DB Schenker Logistics Germany AG & Co. KG
  • 17.8. DHL International GmbH
  • 17.9. DSV A/S
  • 17.10. EVERSANA Life Science Services LLC
  • 17.11. Expeditors International of Washington, Inc.
  • 17.12. FedEx Corporation
  • 17.13. GEODIS S.A.
  • 17.14. Hitachi Transport System, Ltd. (LOGISTEED, Ltd.)
  • 17.15. Kuehne + Nagel International AG
  • 17.16. McKesson Corporation
  • 17.17. Nippon Express Holdings, Inc.
  • 17.18. SF Holding Co., Ltd.
  • 17.19. Sinotrans Limited
  • 17.20. Thermo Fisher Scientific Inc.
  • 17.21. Toll Holdings Pty Ltd
  • 17.22. United Parcel Service of America, Inc.
  • 17.23. XPO, Inc.
  • 17.24. Yusen Logistics Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DENDRITIC CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DENDRITIC CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DENDRITIC CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL STEM CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL STEM CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INACTIVATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INACTIVATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INACTIVATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LIVE ATTENUATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVE ATTENUATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LIVE ATTENUATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DISTRIBUTION MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DISTRIBUTION MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DISTRIBUTION MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PACKAGING & LABELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PACKAGING & LABELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PACKAGING & LABELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSPORTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSPORTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSPORTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AIR TRANSPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AIR TRANSPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AIR TRANSPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EXPRESS AIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EXPRESS AIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EXPRESS AIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL STANDARD AIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL STANDARD AIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL STANDARD AIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RAIL TRANSPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RAIL TRANSPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RAIL TRANSPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ROAD TRANSPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ROAD TRANSPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ROAD TRANSPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SEA TRANSPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SEA TRANSPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SEA TRANSPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL WAREHOUSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL WAREHOUSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL WAREHOUSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AMBIENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AMBIENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AMBIENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHILLED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHILLED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHILLED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MONITORED CHILLED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MONITORED CHILLED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MONITORED CHILLED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL STANDARD CHILLED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL STANDARD CHILLED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL STANDARD CHILLED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CONTROLLED ROOM TEMPERATURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CONTROLLED ROOM TEMPERATURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CONTROLLED ROOM TEMPERATURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MONITORED CONTROLLED ROOM TEMPERATURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MONITORED CONTROLLED ROOM TEMPERATURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MONITORED CONTROLLED ROOM TEMPERATURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL STANDARD CONTROLLED ROOM TEMPERATURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL STANDARD CONTROLLED ROOM TEMPERATURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL STANDARD CONTROLLED ROOM TEMPERATURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL FROZEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL FROZEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL FROZEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL STANDARD FROZEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL STANDARD FROZEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL STANDARD FROZEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ULTRA FROZEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ULTRA FROZEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ULTRA FROZEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AIR FREIGHT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AIR FREIGHT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AIR FREIGHT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RAIL FREIGHT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RAIL FREIGHT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RAIL FREIGHT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ROAD TRANSPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ROAD TRANSPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ROAD TRANSPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SEA FREIGHT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SEA FREIGHT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SEA FREIGHT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ACTIVE PACKAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ACTIVE PACKAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ACTIVE PACKAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PASSIVE PACKAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PASSIVE PACKAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PASSIVE PACKAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIOPHARMACEUTICAL MANUFACTURERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOPHARMACEUTICAL MANUFACTURERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BIOPHARMACEUTICAL MANUFACTURERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL RESEARCH HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL RESEARCH HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL RESEARCH HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 245. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 246. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 248. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 249. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 250. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2032 (USD MILLION)
  • TABLE 251. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2032 (USD MILLION)
  • TABLE 252. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2032 (USD MILLION)
  • TABLE 253. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 254. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 287. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 288. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 290. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 291. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 293. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 294. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 295. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2032 (USD MILLION)
  • TABLE 296. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2032 (USD MILLION)
  • TABLE 297. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2032 (USD MILLION)
  • TABLE 298. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 299. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 302. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 303. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 305. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 306. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 308. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 309. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 310. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2032 (USD MILLION)
  • TABLE 311. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2032 (USD MILLION)
  • TABLE 312. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2032 (USD MILLION)
  • TABLE 313. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 314. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 317. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)

TAB